References
- Yuen MF, Lai CL. Treatment for chronic hepatitis B. Lancet Infect. Dis. 1, 232–241 (2001).
- Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet 362, 2089–2094 (2003).
- Yuen MF, Yuan HJ, Hui CK, Wong WM, Lai CL. Determinants for the development of cirrhosis-related complications and survival in patients with chronic hepatitis B infection. Gut (2005) (In Press).
- Liaw YF, Sung JJ, Chow WC et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 351, 1521–1531 (2004).
- Yuen MF, Hui CK, Cheng CC et al. Long-term follow-up of interferon-α treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 34, 139–145 (2001).
- Yuen MF, Lai CL. Adefovir dipivoxil in chronic hepatitis B infection. Expert Opin. Pharmacother. 5, 2361–2367 (2004).
- Hadziyannis S, Tassopoulos N, Chang TT et al. Adefovir dipivoxil (ADV) demonstrates sustained efficacy in HBeAg-chronic hepatitis B (CHB) patients. J. Hepatol. 42(Suppl. 2), 178 (2005).
- Schinazi RF, Chu CK, Peck A et al. Activities of the four optical isomers of 2´, 3´-dideoxy-3´-thiacytidine (BCH-189) against human immunodeficiency virus Type 1 in human lymphocytes. Antimicrob. Agents Chemother. 36, 672–676 (1992).
- Wang P, Hong, JH, Cooperwood JS, Chu CK. Recent advances in l-nucleosides: chemistry and biology. Antiviral Res. 40, 19–44 (1998).
- Pierra C, Imbach JL, De Clercq et al. Synthesis and antiviral evaluation of some β-l-2’, 3’-dideoxy-5-chloropyrimidine nucleosides and pronucleotides. Antiviral Res. 45, 169–183 (2000).
- Bryant ML, Bridges EG, Placidi L et al. Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrob. Agents Chemother. 45, 229–235 (2001).
- Bryant ML, Bridges EG, Placidi L et al. Anti-HBV specific β-l-2´-deoxynucleosides. Nucleosides Nucleotides Nucleic Acids 20, 597–607 (2001).
- Standring DN, Bridges EG, Placidi L et al. Antiviral β-l-nucleotides specific for hepatitis B virus infection. Antivir. Chem. Chemother. 12(Suppl. 1), 119–129 (2001).
- Hernandez-Santiago B, Placidi L, Cretton-Scott E et al. Pharmacology of β-l-thymidine and β-l-2´-deoxycytidine in HepG2 cells and primary human hepatocytes: relevance to chemotherapeutic efficacy against hepatitis B virus. Antimicrob. Agents Chemother. 46, 1728–1733 (2002).
- Bridges EG, Cretton-Scott E, Zhou XJ et al. The anti-HBV agent β-l-thymidine (LdT) exhibits no observable effects in chronic or developmental toxicity studies. HepDart. Hawaii, USA, 16–20th December (2001).
- Zhou XJ, Lim SG, Lai CL, Pow DM, Brown NA, Myers MW. Pharmacokinetics of β-l-deoxythymidine (LdT) in healthy subjects and patients with chronic hepatitis B virus infection. HepDart. Hawaii, USA, 16–20 December (2001).
- Lai CL, Lim SG, Brown NA et al. A dose-finding study of once-daily oral telbivudine (LdT) in patients with chronic hepatitis B virus infection. Hepatology 40, 719–726 (2004).
- Lai CL, Leung N, Teo EK et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with HBeAg-positive chronic hepatitis B. Gastroenterology (2005) (In Press).
- Yuen, MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors predicting hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 34(4 Pt 1), 785–791 (2001).
- Lai CL, Leung N, Teo EK et al. Phase IIb extended-treatment trial of telbivudine (LdT) vs. lamivudine vs. combination treatment in hepatitis B patients: two-year results. Dig. Dis. Week. Chicago, USA, 14–19th May (2005).